In colon cancer, liver cancer, and breast cancer cells, NF-κB activation hampers β-catenin/TCF activity through upregulation of leucine zipper tumor suppressor 2, which is conversely downregulated in GBM cells to promote β-catenin/TCF activity [186]. The gene discussed is HNF4A; the disease is liver cancer.